BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SkyePharma Inc. (SKYE) Ceases Commercialization of formoterol Certihaler(R) in the United States


12/19/2008 6:41:35 AM

LONDON, UK, 19 December 2008 -- SkyePharma PLC (LSE:SKP.L - News) announces that discussions about commercialising the approved formoterol Certihaler® in the United States in 2009 have ceased. This follows last week's recommendation by the Joint Advisory Committees to the Food and Drug Administration that the benefits did not outweigh the risks in the current asthma indications for Long Acting Beta Agonists (LABAs) administered alone.

Cessation of production for formoterol Certihaler® will result in asset write downs and a related non-cash charge estimated at GBP7 million to GBP8 million. This is likely to be charged in the 2008 results.

Dr. Ken Cunningham, CEO of SkyePharma said, "It is disappointing that formoterol Certihaler® is unlikely to be commercialised, but we remain confident of the prospects of our other pipeline products including FlutiformTM which remains on track for filing in Q1, 2009."

For further information please contact:

SkyePharma PLC

Ken Cunningham, Chief Executive Officer +44 207 491 1777 Peter Grant, Chief Financial Officer

Financial Dynamics David Yates +44 207 831 3113 Jonathan Birt

About SkyePharma PLC Using its proprietary drug delivery technologies, SkyePharma develops new formulations of existing products to provide a clinical advantage and life-cycle extension. The Group has twelve approved products in the areas of oral, inhalation and topical delivery. The Group's products are marketed throughout the world by leading pharmaceutical companies.

For more information, visit http://www.skyepharma.com.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES